BACKGROUND: The links between the p53/MDM2 pathway and the expression of pro-oncogenic immune inhibitory receptors in tumor cells are undefined. In this report, we evaluate whether there is p53 and/or MDM2 dependence in the expression of two key immune receptors, CD276 and PD-L1. METHODS: Proximity ligation assays were used to quantify protein-protein interactions in situ in response to Nutlin-3. A panel of p53-null melanoma cells was created using CRISPR-Cas9 guide RNA mediated genetic ablation. Flow cytometric analyses were used to assess the impact of TP53 or ATG5 gene ablation, as well as the effects of Nutlin-3 and an ATM inhibitor on cell surface PD-L1 and CD276. Targeted siRNA was used to deplete CD276 to assess changes in cell cycle parameters by flow cytometry. A T-cell proliferation assay was used to assess activity of CD4+ T-cells as a function of ATG5 genotype. RESULTS: CD276 forms protein-protein interactions with MDM2 in response to Nutlin-3, similar to the known MDM2 interactors p53 and HSP70. Isogenic HCT116 p53-wt/null cancer cells demonstrated that CD276 is induced on the cell surface by Nutlin-3 in a p53-dependent manner. PD-L1 was also unexpectedly induced by Nutlin-3, but PD-L1 does not bind MDM2. The ATM inhibitor KU55993 reduced the levels of PD-L1 under conditions where Nutlin-3 induces PD-L1, indicating that MDM2 and ATM have opposing effects on PD-L1 steady-state levels. PD-L1 is also up-regulated in response to genetic ablation of TP53 in A375 melanoma cell clones under conditions in which CD276 remains unaffected. A549 cells with a deletion in the ATG5 gene up-regulated only PD-L1, further indicating that PD-L1 and CD276 are under distinct genetic control. CONCLUSION: Genetic inactivation of TP53, or the use of the MDM2 ligand Nutlin-3, alters the expression of the immune blockade receptors PD-L1 and CD276. The biological function of elevated CD276 is to promote altered cell cycle progression in response to Nutlin-3, whilst the major effect of elevated PD-L1 is T-cell suppression. These data indicate that TP53 gene status, ATM and MDM2 influence PD-L1 and CD276 paralogs on the cell surface. These data have implications for the use of drugs that target the p53 pathway as modifiers of immune checkpoint receptor expression.

Department of Anesthesiology and Critical Care Union Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan China

Department of Gastrointestinal Surgery Union Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan China

RECAMO Masaryk Memorial Cancer Institute 656 53 Brno Czech Republic

University of Edinburgh Institute of Genetics and Molecular Medicine Edinburgh Scotland EH4 2XR UK

University of Gdansk International Centre for Cancer Vaccine Science ul Wita Stwosza 63 80 308 Gdansk Poland

Zobrazit více v PubMed

Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature. 1997;387:296–299. PubMed

Oliner JD, Pietenpol JA, Thiagalingam S, Gvuris J, Kinzler KW, Vogelstein B. Oncoprotein Mdm2 conceals the activation domain of tumor suppressor-P53. Nature. 1993;362:857–860. PubMed

Arva NC, Gopen TR, Talbott KE, Campbell LE, Chicas A, White DE, Bond GL, Levine AJ, Bargonetti J. A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells. J Biol Chem. 2005;280:26776–26787. PubMed

Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature. 1997;387:299–303. PubMed

Kussie PH, Gorina S, Marechal V, Elenbaas B, Moreau J, Levine AJ, Pavletich NP. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science. 1996;274:948–953. PubMed

Picksley SM, Vojtesek B, Sparks A, Lane DP. Immunochemical analysis of the interaction of p53 with MDM2;--fine mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogene. 1994;9:2523–2529. PubMed

Bottger A, Bottger V, Sparks A, Liu WL, Howard SF, Lane DP. Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Curr Biol. 1997;7:860–869. PubMed

Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004;303:844–848. PubMed

Cohen P, Tcherpakov M. Will the ubiquitin system furnish as many drug targets as protein kinases? Cell. 2010;143:686–693. PubMed

Sun DQ, Li ZH, Rew Y, Gribble M, Bartberger MD, Beck HP, Canon J, Chen A, Chen XQ, Chow D, et al. Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development. J Med Chem. 2014;57:1454–1472. PubMed

Chang YS, Graves B, Guerlavais V, Tovar C, Packman K, To KH. Olson KA, Kesavan K, Gangurde P, Mukherjee A, et al. Stapled alpha-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy. Proc Natl Acad Sci U S A. 2013;110:E3445–E3454. PubMed PMC

Leach FS, Tokino T, Meltzer P, Burrell M, Oliner JD, Smith S, Hill DE, Sidransky D, Kinzler KW, Vogelstein B. P53 mutation and Mdm2 amplification in human soft-tissue sarcomas. Cancer Res. 1993;53:2231–2234. PubMed

Taylor BS, Barretina J, Maki RG, Antonescu CR, Singer S, Ladanyi M. Advances in sarcoma genomics and new therapeutic targets. Nat Rev Cancer. 2011;11:541–557. PubMed PMC

Ray-Coquard I, Blay JY, Italiano A, Le Cesne A, Penel N, Zhi J, Heil F, Rueger R, Graves B, Ding M, et al. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. Lancet Oncol. 2012;13:1133–1140. PubMed

Khoo KH, Verma CS, Lane DP. Drugging the p53 pathway: understanding the route to clinical efficacy. Nat Rev Drug Discov. 2014;13:217–236. PubMed

Wallace M, Worrall E, Pettersson S, Hupp TR, Ball KL. Dual-site regulation of MDM2 E3-ubiquitin ligase activity. Mol Cell. 2006;23:251–263. PubMed

Yu GW, Rudiger S, Veprintsev D, Freund S, Fernandez-Fernandez MR, Fersht AR. The central region of HDM2 provides a second binding site for p53. Proc Natl Acad Sci U S A. 2006;103:1227–1232. PubMed PMC

Wong JH, Alfatah M, Sin MF, Sim HM, Verma CS, Lane DP, Arumugam P. A yeast two-hybrid system for the screening and characterization of small-molecule inhibitors of protein-protein interactions identifies a novel putative Mdm2-binding site in p53. BMC Biol. 2017;15:108. PubMed PMC

Medina-Medina I, Martinez-Sanchez M, Hernandez-Monge J, Fahraeus R, Muller P, Olivares-Illana V. p53 promotes its own polyubiquitination by enhancing the HDM2 and HDMX interaction. Protein Sci. 2018;27:976–986. PubMed PMC

Landre V, Revi B, Mir MG, Verma C, Hupp TR, Gilbert N, Ball KL. Regulation of transcriptional activators by DNA-binding domain ubiquitination. Cell Death Differ. 2017;24:903–916. PubMed PMC

Dickinson ER, Jurneczko E, Nicholson J, Hupp TR, Zawacka-Pankau J, Selivanova G, Barran PE. The use of ion mobility mass spectrometry to probe modulation of the structure of p53 and of MDM2 by small molecule inhibitors. Front Mol Biosci. 2015;2:39. PubMed PMC

Chae H, Kwak DK, Lee MK, Chi SW, Kim KB. Solid-state nanopore analysis on conformation change of p53TAD-MDM2 fusion protein induced by protein-protein interaction. Nanoscale. 2018;10:17227–17235. PubMed

Schon O, Friedler A, Bycroft M, Freund SMV, Fersht AR. Molecular mechanism of the interaction between MDM2 and p53. J Mol Biol. 2002;323:491–501. PubMed

Pettersson S, Sczaniecka M, McLaren L, Russell F, Gladstone K, Hupp T, Wallace M. Non-degradative ubiquitination of the Notch1 receptor by the E3 ligase IVIDM2 activates the notch signalling pathway. Biochem J. 2013;450:523–536. PubMed

Nicholson J, Neelagandan K, Huart AS, Ball K, Molloy MP, Hupp T. An iTRAQ proteomics screen reveals the effects of the MDM2 binding ligand Nutlin-3 on cellular Proteostasis. J Proteome Res. 2012;11:5464–5478. PubMed

Nicholson J, Scherl A, Way L, Blackburn EA, Walkinshaw MD, Ball KL, Hupp TR. A systems wide mass spectrometric based linear motif screen to identify dominant in-vivo interacting proteins for the ubiquitin ligase MDM2. Cell Signal. 2014;26:1243–1257. PubMed

Way L, Faktor J, Dvorakova P, Nicholson J, Vojtesek B, Graham D, Ball KL, Hupp T. Rearrangement of mitochondrial pyruvate dehydrogenase subunit dihydrolipoamide dehydrogenase protein-protein interactions by the MDM2 ligand nutlin-3. Proteomics. 2016;16:2327–2344. PubMed PMC

Melaiu O, Mina M, Chierici M, Boldrini R, Jurman G, Romania P, D'Alicandro V, Benedetti MC, Castellano A, Liu T, et al. PD-L1 Is a Therapeutic Target of the Bromodomain Inhibitor JQ1 and, Combined with HLA Class I, a Promising Prognostic Biomarker in Neuroblastoma. Clin Cancer Res. 2017;23:4462–4472. PubMed

Zou J, Zhuang M, Yu X, Li N, Mao R, Wang Z, Wang J, Wang X, Zhou H, Zhang L, et al. MYC inhibition increases PD-L1 expression induced by IFN-gamma in hepatocellular carcinoma cells. Mol Immunol. 2018;101:203–209. PubMed

Coelho MA, de Carne TS, Rana S, Zecchin D, Moore C, Molina-Arcas M, East P, Spencer-Dene B, Nye E, Barnouin K, et al. Oncogenic RAS signaling promotes tumor Immunoresistance by stabilizing PD-L1 mRNA. Immunity. 2017;47:1083–1099. PubMed PMC

Fang DD, Tang Q, Kong Y, Wang Q, Gu J, Fang X, Zou P, Rong T, Wang J, Yang D, et al. MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment. J Immunother Cancer. 2019;7:327. PubMed PMC

Newman AC, Kemp AJ, Drabsch Y, Behrends C, Wilkinson S. Autophagy acts through TRAF3 and RELB to regulate gene expression via antagonism of SMAD proteins. Nat Commun. 2017;8:1537. PubMed PMC

Bunz F, Hwang PM, Torrance C, Waldman T, Zhang YG, Dillehay L, Williams J, Lengauer C, Kinzler KW, Vogelstein B. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest. 1999;104:263–269. PubMed PMC

Muller P, Ceskova P, Vojtesek B. Hsp90 is essential for restoring cellular functions of temperature-sensitive p53 mutant protein but not for stabilization and activation of wild-type p53 - implications for cancer therapy. J Biol Chem. 2005;280:6682–6691. PubMed

Chen JD, Marechal V, Levine AJ. Mapping of the P53 and Mdm-2 interaction domains. Mol Cell Biol. 1993;13:4107–4114. PubMed PMC

Vojtesek B, Bartek J, Midgley CA, Lane DP. An immunochemical analysis of the human nuclear Phosphoprotein-P53 - new monoclonal-antibodies and epitope mapping using recombinant-P53. J Immunol Methods. 1992;151:237–244. PubMed

Midgley CA, Fisher CJ, Bartek J, Vojtesek B, Lane D, Barnes DM. Analysis of P53 expression in human tumors - an antibody raised against human P53 expressed in Escherichia-Coli. J Cell Sci. 1992;101:183–189. PubMed

Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013;8:2281–2308. PubMed PMC

Huart AS, MacLaine NJ, Meek DW, Hupp TR. CK1 alpha plays a central role in mediating MDM2 control of p53 and E2F-1 protein stability. J Biol Chem. 2009;284:32384–32394. PubMed PMC

Soderberg O, Leuchowius KJ, Gullberg M, Jarvius M, Weibrecht I, Larsson LG, Landegren U. Characterizing proteins and their interactions in cells and tissues using the in situ proximity ligation assay. Methods. 2008;45:227–232. PubMed

Haaland I, Opsahl JA, Berven FS, Reikvam H, Fredly HK, Haugse R, Thiede B, McCormack E, Lain S, Bruserud O, et al. Molecular mechanisms of nutlin-3 involve acetylation of p53, histones and heat shock proteins in acute myeloid leukemia. Mol Cancer. 2014;13:116. PubMed PMC

Wiech M, Olszewski MB, Tracz-Gaszewska Z, Wawrzynow B, Zylicz M, Zylicz A. Molecular mechanism of mutant p53 stabilization: the role of HSP70 and MDM2. PLoS One. 2012;7:e51426. PubMed PMC

Muller P, Hrstka R, Coomber D, Lane DP, Vojtesek B. Chaperone-dependent stabilization and degradation of p53 mutants. Oncogene. 2008;27:3371–3383. PubMed

Zhuang XH, Shen PG, Jia ZY, Wu AR, Xu T, Shi YQ, Xu CF. Anti-B7-H3 monoclonal antibody ameliorates the damage of acute experimental pancreatitis by attenuating the inflammatory response. Int Immunopharmacol. 2016;35:1–6. PubMed

Guo GN, Shang YJ, Zhu GY, Bao XR, Xu SW, Chen YW. The expression and distribution of immunomodulatory proteins B7-H1, B7-DC, B7-H3, and B7-H4 in rheumatoid synovium. Clin Rheumatol. 2012;31:271–281. PubMed

Van Der Kraak L, Goel G, Ramanan K, Kaltenmeier C, Zhang L, Normolle DP, Freeman GJ, Tang D, Nason KS, Davison JM, et al. 5-fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers. J Immunother Cancer. 2016;4:65. PubMed PMC

Blaydes JP, Luciani MG, Pospisilova S, Ball HML, Vojtesek B, Hupp TR. Stoichiometric phosphorylation of human p53 at Ser(315) stimulates p53-dependent transcription. J Biol Chem. 2001;276:4699–4708. PubMed

Ahmed MM, Venkatasubbarao K, Fruitwala SM, Muthukkumar S, Wood DP, Sells SF, Mohiuddin M, Rangnekar VM. EGR-1 induction is required for maximal radiosensitivity in A375-C6 melanoma cells. J Biol Chem. 1996;271:29231–29237. PubMed

Lain S, Hollick JJ, Campbell J, Staples OD, Higgins M, Aoubala M, McCarthy A, Appleyard V, Murray KE, Baker L, et al. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell. 2008;13:454–463. PubMed PMC

Lee J, Kefford R, Carlino M. PD-1 and PD-L1 inhibitors in melanoma treatment: past success, present application and future challenges. Immunotherapy. 2016;8:733–746. PubMed

Pang LY, Scott M, Hayward RL, Mohammed H, Whitelaw CBA, Smith GCM, Hupp TR. p21(WAF1) is component of a positive feedback loop that maintains the p53 transcriptional program. Cell Cycle. 2011;10:932–950. PubMed

Cha JH, Yang WH, Xia W, Wei Y, Chan LC, Lim SO, Li CW, Kim T, Chang SS, Lee HH, et al. Metformin promotes antitumor immunity via endoplasmic-reticulum-associated degradation of PD-L1. Mol Cell. 2018;71:606–620. PubMed PMC

Xilouri M, Stefanis L. Chaperone mediated autophagy in aging: starve to prosper. Ageing Res Rev. 2016;32:13–21. PubMed

Kim JH, Hong SB, Lee JK, Han S, Roh KH, Lee KE, Kim YK, Choi EJ, Song HK. Insights into autophagosome maturation revealed by the structures of ATG5 with its interacting partners. Autophagy. 2015;11:75–87. PubMed PMC

Wang XJ, Wu WKK, Gao J, Li ZW, Dong B, Lin XT, Li YL, Li YY, Gong JF, Qi CS, et al. Autophagy inhibition enhances PD-L1 expression in gastric cancer. J Exp Clin Canc Res. 2019;38:140. PubMed PMC

Borthakur G, Duvvuri S, Ruvolo V, Tripathi DN, Piya S, Burks J, Jacamo R, Kojima K, Ruvolo P, Fueyo-Margareto J, et al. MDM2 inhibitor, Nutlin 3a, induces p53 dependent autophagy in acute leukemia by AMP kinase activation. PLoS One. 2015;10:e0139254. PubMed PMC

Xie C, Liu DQ, Chen QJ, Yang C, Wang B, Wu HS. Soluble B7-H3 promotes the invasion and metastasis of pancreatic carcinoma cells through the TLR4/NF-kappa B pathway. Sci Rep-Uk. 2016;6:27528. PubMed PMC

Schon O, Friedler A, Freund S, Fersht AR. Binding of p53-derived ligands to MDM2 induces a variety of long range conformational changes. J Mol Biol. 2004;336:197–202. PubMed

Huart AS, MacLaine NJ, Narayan V, Hupp TR. Exploiting the MDM2-CK1 alpha protein-protein Interface to develop novel biologics that induce UBL-kinase-modification and inhibit cell growth. PLoS One. 2012;7:e43391. PubMed PMC

Blaydes JP, Hupp TR. DNA damage triggers DRB-resistant phosphorylation of human p53 at the CK2 site. Oncogene. 1998;17:1045–1052. PubMed

Tsai KK, Zarzoso I, Daud AI. PD-1 and PD-L1 antibodies for melanoma. Hum Vacc Immunother. 2014;10:3111–3116. PubMed PMC

Newman AC, Scholefield CL, Kemp AJ, Newman M, McIver EG, Kamal A, Wilkinson S. TBK1 kinase addiction in lung Cancer cells is mediated via autophagy of Tax1bp1/Ndp52 and non-canonical NF-kappa B Signalling. PLoS One. 2012;7:e50672. PubMed PMC

Picarda E, Ohaegbulam KC, Zang XX. Molecular pathways: targeting B7-H3 (CD276) for human Cancer immunotherapy. Clin Cancer Res. 2016;22:3425–3431. PubMed PMC

Lane DP, Verma C. Mdm2 in evolution. Genes & cancer. 2012;3:320–324. PubMed PMC

Karakostis K, Ponnuswamy A, Fusee LT, Bailly X, Laguerre L, Worall E, Vojtesek B, Nylander K, Fahraeus R. p53 mRNA and p53 protein structures have evolved independently to interact with MDM2. Mol Biol Evol. 2016;33:1280–1292. PubMed

Errico A. PD-1-PD-L1 axis: efficient checkpoint blockade against cancer. Nat Rev Clin Oncol. 2015;12:63. PubMed

Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013;14:1014–1022. PubMed PMC

Cortez MA, Ivan C, Valdecanas D, Wang X, Peltier HJ, Ye Y, Araujo L, Carbone DP, Shilo K, Giri DK, et al. PDL1 Regulation by p53 via miR-34. J National Cancer Institute. 2016;108:djv303. PubMed PMC

Inverse correlation between TP53 gene status and PD-L1 protein levels in a melanoma cell model depends on an IRF1/SOX10 regulatory axis

Resistance mechanisms to inhibitors of p53-MDM2 interactions in cancer therapy: can we overcome them?

An integrated DNA and RNA variant detector identifies a highly conserved three base exon in the MAP4K5 kinase locus